Novo Nordisk's weight-loss drugs aren't the only game in town. That's bad news for its high-flying share price. The Danish maker of the Ozempic and Wegovy drugs has seen its share price fall 7% over the past two days.

Novo Nordisk, the maker of Ozempic and Wegovy, continues to enjoy booming sales, but supply constraints and pricing concerns are putting pressure on the stock.Why it matters: The company's weight-loss and diabetes drugs have transformed the Danish drug giant into one of the hottest stocks on the market.

Wegovy prices in the United States were "slightly down" in the first quarter and Novo expects further decreases through the rest of 2024,